PlexPCR® RespiVirus received clearance from the Australian Therapeutic Goods Administration (TGA), bringing much needed workflow advantages in time for the busy 2019 flu season. The test utilises market-leading multiplex technology to detect 11 viral respiratory-illness causing pathogens and allows laboratories to process more samples in an 8-hour shift compared to standard in-house test methods.
“We are so pleased to be in a position to support Australian laboratories for what is already proving to be a very busy flu season,” said Colin Denver, SpeeDx CEO.
Australian surveillance has recorded an unprecedented number of influenza cases in 2019 – with over four times the number of confirmed cases, compared with the first quarter year average.
Read the full press release.